The Burst and Pulse Method: A Structured Approach to Neuroinflammation Management with Psychedelics

Most people who find this article aren’t looking for help with ordinary aches and pains. They’re dealing with something more entrenched: a diagnosis with neuroinflammation at its root, a cognitive trajectory they’re trying to change, a body that has been in a state of low-grade inflammatory alarm for years. Or they’ve been paying attention to the research on brain aging and want to be proactive about it.

That’s the context this article is written for.

At Eleusinia, we’ve developed the Burst and Pulse Method as a structured framework for using psilocybin and DMT to address neuroinflammation. This article explains what neuroinflammation is, why psychedelics may be relevant to it, how the method works, and where the evidence is still incomplete.

What Is Neuroinflammation and Why Does It Matter

Neuroinflammation is inflammation occurring within the brain and central nervous system. It’s driven primarily by microglia, the brain’s resident immune cells, which release pro-inflammatory cytokines in response to injury, infection, metabolic stress, or systemic inflammation that crosses the blood-brain barrier.

In acute situations, this is appropriate and protective. The problem arises when the inflammatory state becomes chronic. Persistently activated microglia, elevated cytokines, and oxidative stress in neural tissue appear to be significant drivers of several serious conditions:

Alzheimer’s disease and cognitive aging. Neuroinflammation is now understood to be a central feature of Alzheimer’s pathology, not just a byproduct of it. Chronic microglial activation promotes amyloid accumulation and tau pathology, and elevated inflammatory markers in midlife are associated with worse cognitive outcomes decades later. This has shifted thinking in the field toward prevention: reducing the neuroinflammatory burden earlier, before significant damage accumulates, may be more tractable than treating late-stage disease.

Multiple sclerosis. Neuroinflammation is the primary driver of demyelination in MS, making anti-inflammatory approaches a central therapeutic target.

Long COVID and post-infectious neuroinflammation. A growing body of evidence links persistent neuroinflammation to the cognitive symptoms (“brain fog”), fatigue, and dysautonomia that characterize long COVID and similar post-infectious syndromes.

Chronic pain with central sensitization. Many chronic pain conditions involve neuroinflammatory components, where the nervous system itself becomes sensitized and amplifies pain signals independently of ongoing tissue damage.

This is the landscape in which the Burst and Pulse method operates.

How Psychedelics Interact with Neuroinflammation

Psilocybin’s primary mechanism is activation of the 5-HT2A serotonin receptor, which is expressed in both neurons and immune cells and plays a role in regulating inflammatory signaling. Two effects are particularly relevant:

Neuroplasticity. Psilocybin promotes dendritic spine growth and synapse formation. This is one of the better-supported findings in the psychedelic literature. In the context of neuroinflammation, where chronic inflammation degrades synaptic function and accelerates neural circuit deterioration, restoring neuroplasticity may be both directly beneficial and synergistic with reducing inflammation.

Cytokine modulation. Psilocybin appears to influence pro-inflammatory cytokines, but the evidence here is more complicated than it’s often presented. A double-blind, placebo-controlled human study found that psilocybin rapidly reduced TNF-alpha while reductions in IL-6 and CRP appeared later, at the seven-day measurement point. IL-1beta did not show significant changes in that study. A separate retrospective analysis of serum from multiple clinical trials found a different pattern: TNF-alpha and IL-8 actually increased within one week post-administration, with anti-inflammatory shifts (elevated IL-10 and IFN-alpha) appearing only at four weeks or later.

These findings don’t invalidate each other, but they tell us the inflammatory response to psilocybin is not a simple or immediate suppression. Timing, baseline inflammation levels, and individual factors all appear to matter. The field does not yet have a clean mechanistic picture, and we’ll be direct about that throughout this article.

The Sigma-1 Receptor: DMT’s Additional Pathway
DMT (dimethyltryptamine) activates the 5-HT2A receptor like psilocybin, but also binds to the Sigma-1 receptor, which is expressed throughout the brain and nervous system and plays a specific role in neuroinflammation regulation.

In vitro research using human immune cells found that DMT inhibited pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha, IL-8) while increasing anti-inflammatory IL-10 via a Sigma-1-dependent mechanism. Animal research has shown DMT reducing neuroinflammation and stabilizing the blood-brain barrier following stroke. Sigma-1 receptor activation also appears to modulate NF-kB signaling, a central pathway in chronic neuroinflammation, and to influence microglial behavior.

Notably, one mouse model study examining DMT in the context of Alzheimer’s-like pathology found that DMT’s effects were complicated by its dual activity at both 5-HT receptors and Sigma-1, with mixed results on neurogenesis. This is a reminder that the mechanistic story is cleaner in theory than in practice.

Most of the Sigma-1 evidence comes from in vitro or animal studies. Human data on DMT’s specific neuroinflammatory effects is limited. For people dealing with neuroinflammatory conditions, the dual-receptor action is a plausible rationale for including DMT in a structured protocol.

Why One Session Is Not Enough

A single psychedelic session can produce meaningful acute effects, but neuroinflammation that has been present for months or years does not resolve from a single intervention. This is true of most anti-inflammatory approaches: the inflammatory pressure continues, and without repeated or sustained intervention, the system trends back toward its prior state.

The timing hypothesis at the center of the Burst and Pulse method is biologically plausible but not yet directly confirmed in clinical trials. The logic is this: anti-inflammatory effects following a psychedelic session are not permanent. Inflammatory markers likely begin recovering toward baseline in the days following exposure. If the next exposure happens before full recovery, the compounding effect starts from an already-reduced baseline rather than from zero. Over multiple repetitions within a cluster, the goal is to drive that baseline incrementally lower.

The alternative, spacing the same number of sessions across a year with months between each, probably doesn’t produce the same effect. You may be returning to near-baseline each time, which means each session is starting over rather than building.

This is also why microdosing is unlikely to serve this specific purpose. The anti-inflammatory mechanism appears to be dose-dependent, requiring sufficient receptor occupancy to produce meaningful cytokine modulation. Doses too small to produce perceptible effects are probably too small to move the neuroinflammatory needle.

How the Method Works

The method has two components:

The Burst (Macrodose). A full-dose psilocybin session that creates the initial neuroplastic and anti-inflammatory shift. This is the primary intervention and requires proper preparation, a safe setting, and trained support.

The Pulse (Reinforcement Doses). A series of lower-dose sessions over the following four weeks, timed to sustain the anti-inflammatory effect before it dissipates. DMT is particularly well-suited for pulse doses due to its short duration: a vaporized session lasts 10-15 minutes versus 4-6 hours for psilocybin, making it practical for repeated use within a cluster. Lower-dose psilocybin (0.5-1.0g) is an alternative for those without access to DMT.

After completing the four-week cluster, the protocol calls for a rest period and symptom monitoring before deciding whether to repeat. Most people do one to two clusters per year. The clustering is the mechanism: a tight sequence of exposures compounding from a reduced baseline, not a vague commitment to “doing psychedelics regularly.”

Example Schedules:

Psilocybin Burst with DMT Pulses

Day 1: Psilocybin macrodose
Every 3-4 days: DMT pulse dose
Duration: 4 weeks, then rest and monitor

Psilocybin Burst with Psilocybin Pulses

Day 1: Psilocybin macrodose
Every 5 days: Psilocybin minidose (0.5-1.0g)
Duration: 4 weeks, then rest and monitor

What We Don’t Know

The Burst and Pulse method is a clinical framework built from available research, mechanistic reasoning, and observation from our program. It is not a proven protocol with randomized controlled trial data behind it. Specifically:

• The precise timeline for neuroinflammatory recovery after a psychedelic session has not been directly measured in humans, which means the optimal interval between pulse doses is not established.
• The human cytokine data is mixed. Some studies show short-term pro-inflammatory changes before anti-inflammatory ones emerge, which raises open questions about how the inflammatory response evolves over the days and weeks following a session.
• Individual variation is significant. People with different baseline inflammation levels, different underlying conditions, and different dose responses may need meaningfully different approaches.
• Long-term effects of repeated structured psychedelic use on neuroinflammation have not been studied in controlled settings.

We are transparent about this because the psychedelic space has a tendency toward overclaiming, and people dealing with serious neurological conditions deserve accurate information. The evidence is promising and the mechanistic reasoning is sound. Approach it as a well-grounded hypothesis, not a settled treatment.

Practical Considerations

Supervision. Macrodose sessions require a safe setting and trained facilitation. This is not a method for unsupported self-experimentation, especially for people managing neurological conditions.

Sleep. Psilocybin can cause temporary insomnia in the hours following ingestion. Plan sessions for morning or late morning. Persistent sleep disruption after a session is not normal and should not be dismissed.

Frequency. The four-week cluster uses lower reinforcement doses, not repeated macrodoses. Frequent high-dose experiences are cognitively and emotionally demanding and are not the goal here.

Complementary approaches. Anti-inflammatory nutrition, sleep hygiene, aerobic exercise, and stress reduction all work on neuroinflammation through independent mechanisms. Psychedelics are not a substitute for these; they’re a potential addition that may produce effects the others can’t.

A Note on Expectations

The Burst and Pulse method is not a cure for any neuroinflammatory condition. It is a structured approach to using tools that may reduce the neuroinflammatory burden and support the brain’s capacity to repair and rewire. Results vary. The goal is incremental improvement in baseline function over time, ideally measured rather than assumed.

For people interested in cognitive aging and Alzheimer’s prevention specifically, the most honest framing is this: the window for meaningful intervention is probably earlier than most people think, and the absence of symptoms is not the same as the absence of neuroinflammation. If this approach interests you as a preventive strategy, that’s a legitimate reason to explore it, and the evidence base for that framing is, if anything, more coherent than for late-stage intervention.

If you’re considering this approach, work with practitioners who understand the pharmacology, can assess your individual situation honestly, and will be direct with you about what the evidence does and does not support.

How Psychedelics Compare to Traditional Pain and Inflammation Treatments

Treatment	Effect	Side Effects	Limitations
NSAIDS	Reduces inflammation	Can cause ulcers, kidney issues	Long-term use can damage liver and kidneys
Opioids	Blocks pain signals	High addiction risk, gastrointestinal issues (constipation, nausea)	Does not address underlying cause of pain
Corticosteroids	Suppresses inflammation	Weight gain, bone necrosis, adrenal suppression	Long-term use weakens immune function and bone damage
Monoclonal Antibodies	Targets specific inflammatory cytokines	Risk of infections, high cost	Do not cross the blood-brain barrier, limiting impact on neuroinflammation
Triptans	Constricts blood vessels, blocks migraine pain pathways	Risk of cardiovascular effects, dizziness, nausea	Not effective for all headache types, overuse can lead to rebound headaches, elevated risk of stroke after 65
Psychedelics	Rewires pain pathways, reduces inflammation	Minimal long-term side effects, requires structured use and supervision	Still under research, legal restrictions

Mindset, Integration, and Responsible Use

Psychedelics are powerful tools, but they work best when combined with an intentional approach. At Eleusinia, we emphasize:

• Structured Preparation: Safe, intentional use with proper guidance.
• Integration Practices: Meditation, movement therapy, and journaling to track progress and identify patterns.
• Getting enough sleep is crucial. Psilocybin can cause temporary insomnia in the 8 hours after ingestion, so always plan your doses in the early or late morning. Lack of sleep in the days following a psychedelic experience can be an indication of a serious complication.

Frequent high-dose experiences can be overwhelming, so tailoring the approach to your needs is key.